Overview

Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)

Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare long-term safety and tolerability of stavudine (d4T) extended release (ER) versus conventional (immediate release [IR]) formulations, each in combination with lamivudine (3TC) and efavirenz (EFV) in subjects who have completed Bristol-Myers Squibb (BMS) studies AI455-096 and AI455-099.
Phase:
Phase 3
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Efavirenz
Lamivudine
Stavudine